Recruitmenttrust

https://www.accessdata.fda.gov › drugsatfda_docs › nda
In response to DO2 s consult request dated November 28 2023 OPDP has reviewed the proposed Prescribing Information PI and

https://ctv.veeva.com › study › a-study-of...
This is a Phase III IV single arm multicenter study of the long term safety and efficacy of atezolizumab treatment in

https://clinicaltrials.gov › study
An Open Label Singe Arm Multicenter Study to Investigate the Safety and Efficacy of Atezolizumab Tecentriq in Previously

https://clinicaltrials.eu › trial › long-term-study...
This clinical trial is focused on studying the effects of a medication called atezolizumab which is marketed under the name Tecentriq

https://www.accessdata.fda.gov › drugsatfda_docs › nda
Any changes in the manufacturing testing packaging or labeling of Tecentriq Hybreza or in the manufacturing facilities will require

https://www.ncbi.nlm.nih.gov › books
Based on CADTH s assessment of the health economic evidence Tecentriq does not represent good value to the health care

https://www.roche.com › media › releases
The FDA approval is based on results from the phase III IMforte study which showed that the Tecentriq and

https://www.ema.europa.eu › en › documents › rmp › ...
Tecentriq in combination with nab paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or

https://cdn.clinicaltrials.gov › large-docs
A PHASE III IV SINGLE ARM MULTICENTER STUDY OF ATEZOLIZUMAB TECENTRIQ TO INVESTIGATE LONG TERM